原子加速器官网3.2旧版-ios加速器
- Login to My AlzForum
- Jump to the Search form
NEWS
原子加速器官网3.2旧版-ios加速器
A slight drop in hospital admissions after amyloid PET, especially in people with positive scans, fell well short of the prespecified endpoint. Still, IDEAS is broadening into a research platform, and IDEAS 2 will add racial diversity.
原子加速器官网3.2旧版-ios加速器
New genetic variants emerged by harmonizing whole-exome-sequencing data across continents, and by using imputation to plumb the depths of existing GWAS. One variant encodes a microglial phospholipid transporter.
原子加速器官网3.2旧版-ios加速器
门户页面友链劫持 - 反馈和投诉 - Minecraft(我的世界)中文论坛:2021-9-28 · 我的世界官网 中文百科(镜像) 身份认证 服务器列表 搜索 搜索 本版 用户 注册 登录 帐号 自动登录 找回密码 密码 登录 注册(register) 只需一步，立刻登录 首页 Portal 论坛 Forum 小组 Groups ...
原子加速器官网3.2旧版-ios加速器
In large population datasets, people who had been vaccinated against influenza or pneumonia appeared less likely to develop AD.
原子加速器官网3.2旧版-ios加速器
This early marker distinguishes Alzheimer’s from controls and other neurodegenerative diseases more accurately than other biomarkers.
原子加速器官网3.2旧版-ios加速器
Poor coordination among grid cells in the entorhinal cortex and place cells in the hippocampus compromises navigation. Grid cells fail first.
原子加速器官网3.2旧版-ios加速器
This neuronal protein regulates the complement cascade in the developing brain. Could it do the same in aging or neurodegenerative disease?
原子加速器官网3.2旧版-ios加速器
In striatal spiny projection neurons with mutant huntingtin, mitochondria spill immunogenic RNAs into the cytosol. These touch off innate antiviral signaling inside the neurons, which may spell their demise.
View All News
原子加速器官网3.2旧版-ios加速器
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Dash Genomics, Inc., Abcam, BrainXell, and the Jackson Laboratory.
SPOTLIGHT
Finally: The Alzheimer’s Blood Test We’ve Always Wanted?
In two new papers and several presentations at this year’s AAIC, researchers describe how p-tau217 in the plasma distinguishes people with Alzheimer’s disease from healthy controls and from people with related disorders. The test posts a stunning degree of accuracy and boasts a comfortable dynamic range. Plasma p-tau217 levels, which seem specific for people who have just begun to deposit amyloid plaques, begin to rise two decades before symptoms or appreciable neurofibrillary tangles. Will this test transform Alzheimer’s research, drug development, and care?
expressvnp中文官网
Professional Resources
New in last 7 days
-
Grants
- New Items: 3
- Total Items: 99
-
expressvnp中文官网
- expressvnp中文官网3
- Total Items: 57
-
Conference Calendar
- New Items: 4
- Total Items: 67
- Member Directory
Latest Comments